Source comparison
Comparison: Thymosin Alpha-1 vs Other Immune Modulators in Autoimmune Models
Thymosin Alpha-1 TLR9 agonism → dendritic cell tolerization → Treg expansion Increases Tregs 40–65%, reduces Th17 60–70% Strong preclinical data in SLE, RA, MS models with measurable disease score reductions Human trial data limited; optimal dosing and timing
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR9 agonism → dendritic cell tolerization → Treg expansion
- Increases Tregs 40–65%, reduces Th17 60–70%
- Strong preclinical data in SLE, RA, MS models with measurable disease score reductions
- Human trial data limited; optimal dosing and timing windows not fully defined
- Most promising for early-stage intervention before irreversible tissue damage. Addresses root immune dysregulation rather than symptom suppression
- Low-Dose IL-2
- Direct IL-2 receptor stimulation preferentially expands Tregs
- Increases Tregs 30–50%, minimal Th17 effect
- Phase 2 trials in SLE, type 1 diabetes show Treg expansion but inconsistent clinical benefit
- Narrow therapeutic window; higher doses activate effector T-cells and worsen inflammation
- Cleaner mechanism than thymosin alpha-1 but harder to dose correctly in practice. One dose miscalculation reverses the intended effect
- Vitamin D3 (Calcitriol)
- VDR activation in T-cells and dendritic cells → reduced Th17 differentiation
- Reduces Th17 modestly, Treg effect variable
- Observational links between low vitamin D and autoimmune flares; RCTs show minimal disease modification
- Weak magnitude of effect; unreliable Treg induction
- Safe and cheap but insufficient as monotherapy. Useful adjunct, not a primary modulator
- Rapamycin (mTOR inhibitor)
- mTOR blockade promotes Treg differentiation and stability
- Increases Tregs 50–80%, blocks Th17 via metabolic restriction
- Strong mechanistic data; small lupus nephritis trial showed reduced proteinuria
- Broad metabolic effects cause dose-limiting toxicity (hyperlipidemia, infections, delayed wound healing)
- Powerful immune rebalancing but too toxic for chronic autoimmune use outside transplant settings